The new government's manifesto included positive ambitions for the UK's life sciences. We look forward to working with them, the sector and all the parties to keep making life science life-changing.

Read our new profile on Professor James Chalmers: "A maverick making an impact in bronchiectasis" tinyurl.com/ycxn5hs8

An important announcement from LifeArc, DDTD and Novarum DX Ltd on a smartphone app that could help with the detection of river blindness and elephantiasis, two tropical diseases that affect more than 150m people worldwide.

Did you know that the field of bronchiectasis (BE) has unrealised commercial and research potential? There is a big gap in the market for new BE drugs and diagnostics. We're always looking for new projects to collaborate on! Find out more: t.ly/YeIsK

Head of LifeArc Ventures Clare Terlouw spoke at Medicines Discovery Catapult Connects 2024 webinar ‘Unlocking the Secrets of Medicine Commercialisation’. Read Clare's view on commercialising innovation and establishing the right valuation for a transaction. lnkd.in/eh8HaxCD LifeArc

We’re working together with LifeArc to progress research into bronchiectasis. By giving patients a voice, we can help inform the development of new innovations and identify key areas of unmet need that need addressing. orlo.uk/A4lMp

Bronchiectasis (BE) is the UK's third most common chronic lung condition, yet it is surrounded by misconceptions. James D Chalmers debunks these common misconceptions. Passionate about BE? Learn how we can work together: t.ly/KizRl Asthma + Lung UK Asthma + Lung UK Research

We're funding a new clinical trial exploring the potential of repurposing three antiinflammatory drugs to treat bronchiectasis. If successful, this trial could offer hope to over 200,000 people who suffer from bronchiectasis in the UK. Read more: t.ly/zhU5U

Today’s MHRAgovuk approval of lecanemab is a great step in the right direction for the treatment of Alzheimer’s. While NICE's decision not to make it available on the NHS is difficult, we hope more people will have access to lecanemab over time. bit.ly/3Ax0lFx

One million brain scans used to assess dementia risk bbc.com/news/articles/…

Great coverage today of a new research project that is using AI and machine learning to analyse MRI scans to determine the risk of developing dementia. LifeArc are a key partner in the NEURii research collaboration driving this forward. bbc.co.uk/news/articles/…

Dr Arietta Spinou of King's College London highlights the need for collaboration to advance bronchiectasis research - a common yet overlooked lung condition. We're eager to partner with others in this space! Find out how to collaborate: t.ly/kkYJa

“Thanks to #OurFutureHealth and its volunteers we can make data-based discoveries that can impact people’s lives much quicker.” Dr Dave Powell from our funding charity LifeArc shares how our programme will benefit research into diseases like Alzheimer’s. ourfuturehealth.org.uk/news/lifearc-i…

It's #ChildhoodCancerAwarenessMonth. We aim to drive the development of life-changing innovations for children with cancer through our new Childhood Cancer Translational Challenge strategy, launching later this month. lifearc.org/translational-…

We've joined forces with Cancer Research Horizons and Cancer Research UK to create C-Further, an international consortium dedicated to accelerating the development of new childhood cancer treatments. Read more: t.ly/aL553

.LifeArc have joined forced with Cancer Research Horizons to launch a new international consortium, C-Further developing new therapies for children’s & young people’s #Cancer 👇 bit.ly/46Ww3bh

This is exciting news to share! Congratulations to Cancer Research Horizons and LifeArc on the launch of the C-Further consortium. There’s an urgent need for new treatments tailored for childhood cancers and, thanks to C-Further bringing together a plethora of people within the cancer